Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
SIGA Technologies Inc. (SIGA)
US:NASDAQ Investor Relations:
investor.siga.com/investor-relations
Company Research
Source: GlobeNewswire
Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults affirm tecovirimat’s strong safety profileEfficacy in patients with more severe disease not assessed in study NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analysis of the Study of Tecovirimat for Human Mpox Virus (STOMP) clinical trial (NCT05534984). NIAID reported that SIGA’s tecovirimat, a highly targeted antiviral treatment, did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo in patients with mild to moderate clade II mpox. Based on this and additional analyses, the study Data Safety and Monitoring Board (DSMB) recommended to stop enrolling patients in the randomized arms of the study. NIAID acc
Show less
Read more
Impact Snapshot
Event Time:
SIGA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SIGA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SIGA alerts
High impacting SIGA Technologies Inc. news events
Weekly update
A roundup of the hottest topics
SIGA
News
- Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced [Yahoo! Finance]Yahoo! Finance
- Siga Technologies (SIGA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]Yahoo! Finance
- SIGA Technologies Vs. Emergent BioSolutions: Product Portfolio And Future Outlook [Seeking Alpha]Seeking Alpha
- Are Investors Undervaluing Siga Technologies (SIGA) Right Now? [Yahoo! Finance]Yahoo! Finance
SIGA
Sec Filings
- 12/13/24 - Form 8-K
- 12/10/24 - Form 8-K
- 11/8/24 - Form SC
- SIGA's page on the SEC website